Pebblebrook Hotel Trust (NYSE: PEB) (the “Company”) today announced that
its Board of Trustees has authorized, and the Company has declared, a
quarterly cash dividend of $0.23 per common share of beneficial
interest, to be paid on January 15, 2015 to shareholders of record as of
December 31, 2014 (the “Record Date”). The common dividend represents an
annualized yield of approximately 2.1% based on the closing price of the
common shares on December 12, 2014.
CF101 is currently one of the few Oral Drugs developed for Glaucoma A US Patent for the utilization of CF101 for Glaucoma Treatment will be Valid until 2030
The Glaucoma Market Size is estimated to be approximately $3B PETACH TIKVA, Israel , Dec.
Chesapeake Energy Corporation (NYSE:CHK) today announced that its Board
of Directors has declared a $0.0875 per share quarterly dividend that
will be paid on January 31, 2015 to common shareholders of record on
January 15, 2015.
Acorda Therapeutics, Inc. (Nasdaq: ACOR )
today announced that the first patient has been enrolled in a Phase 3
clinical trial of dalfampridine for the treatment of post-stroke walking
“Approximately three and a half million stroke survivors in the U.S.
suffer ongoing mobility issues.
Kindred Healthcare, Inc. (“Kindred” or the “Company”) (NYSE:KND) today
announced that it has entered into an incremental joinder to increase
the available credit capacity from $750 million to $900 million under
its senior secured asset-based revolving credit facility (the “ABL
The increase in the borrowing capacity will be effective upon completion
of the Company’s merger with Gentiva Health Services, Inc. (“Gentiva”),
which is expected in the first quarter of 2015.
MEDNAX, Inc. (NYSE: MD), the national medical group specializing in
neonatal, anesthesia, maternal-fetal, pediatric cardiology, and other
pediatric physician services, today announced the commencement of a $200
million accelerated share repurchase (ASR) program with JPMorgan Chase
Under the terms of the ASR, MEDNAX will repurchase $200 million of its
common stock, with an aggregate initial delivery of approximately 2.5
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology
biotechnology company, today announced that it has entered into an
amendment to its license agreement with Nerviano Medical Sciences,
S.r.l. relating to its entrectinib (formerly RXDX-101) product
- Almost all holiday shoppers surveyed (93%) have had to purchase a last-minute gift at some point - Nearly 7 in 10 holiday shoppers surveyed would rather do their last-minute shopping in a store than online
- Last-minute shoppers cite indecision (43%) as the leading cause for having to purchase gifts in the 11th hour AUSTIN, Texas , Dec.
plc (NASDAQ: ALKS) today announced the initiation of a phase 1
clinical study of extended dosing intervals of aripiprazole lauroxil,
the company’s investigational, novel, long-acting injectable atypical
antipsychotic for the treatment of schizophrenia.
ROSH HAAYIN, Israel , December 15, 2014 /PRNewswire/ --
In accordance with Section 318(b) of the Israeli Companies Law, 5769-1999 (the " Companies Law ") and Regulation 3 of the Israeli Companies Regulations (Merger), 5770-2000, Pointer Telocation Ltd.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.